These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30866053)

  • 1. Birch pollen allergen-specific immunotherapy with glutaraldehyde-modified allergoid induces IL-10 secretion and protective antibody responses.
    Rauber MM; Wu HK; Adams B; Pickert J; Bohle B; Shamji MH; Pfützner W; Möbs C
    Allergy; 2019 Aug; 74(8):1575-1579. PubMed ID: 30866053
    [No Abstract]   [Full Text] [Related]  

  • 2. The Impact on Allergy-Related Cells of a Birch Pollen Allergoid, with and without Monophosphoryl Lipid A, in Comparison with the Native Equivalent.
    Worm M; Ernst D; Kraller M; Babina M
    Int Arch Allergy Immunol; 2017; 172(1):20-26. PubMed ID: 28219062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
    Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
    J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and immunological correlates of pre-co-seasonal sublingual immunotherapy with birch monomeric allergoid in patients with allergic rhinoconjunctivitis.
    Burastero SE; Mistrello G; Paolucci C; Breda D; Roncarolo D; Zanotta S; Falagiani P
    Int J Immunopathol Pharmacol; 2009; 22(2):343-52. PubMed ID: 19505388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
    Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
    J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
    Larenas-Linnemann D
    Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of allergen composition and in vivo immunogenicity of depigmented allergoids of Betula alba.
    Carnés J; Himly M; Gallego M; Iraola V; Robinson DS; Fernández-Caldas E; Briza P
    Clin Exp Allergy; 2009 Mar; 39(3):426-34. PubMed ID: 19134021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical modification of birch allergen extract leads to a reduction in allergenicity as well as immunogenicity.
    Würtzen PA; Lund L; Lund G; Holm J; Millner A; Henmar H
    Int Arch Allergy Immunol; 2007; 144(4):287-95. PubMed ID: 17641548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
    Vrtala S; Fohr M; Campana R; Baumgartner C; Valent P; Valenta R
    Vaccine; 2011 Mar; 29(11):2140-8. PubMed ID: 21215346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical Impact of Bet v 6 in Birch Pollen-Sensitized Patients.
    Gellrich D; Eder K; San Nicoló M; Berghaus A; Gröger M
    Int Arch Allergy Immunol; 2017; 173(1):34-43. PubMed ID: 28494455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
    Buczyłko K; van der Werf JF; Boot D; van Ree R
    Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis.
    Keen C; Johansson S; Reinholdt J; Benson M; Wennergren G
    Pediatr Allergy Immunol; 2005 May; 16(3):209-16. PubMed ID: 15853949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy.
    Lund L; Henmar H; Würtzen PA; Lund G; Hjortskov N; Larsen JN
    Clin Exp Allergy; 2007 Apr; 37(4):564-71. PubMed ID: 17430354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization.
    Movérare R; Westritschnig K; Svensson M; Hayek B; Bende M; Pauli G; Sorva R; Haahtela T; Valenta R; Elfman L
    Int Arch Allergy Immunol; 2002 Aug; 128(4):325-35. PubMed ID: 12218371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allergen immunotherapy for birch pollen-allergic patients: recent advances.
    Moingeon P; Floch VB; Airouche S; Baron-Bodo V; Nony E; Mascarell L
    Immunotherapy; 2016 May; 8(5):555-67. PubMed ID: 27140409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate and lymphocytic response of birch-allergic patients before and after sublingual immunotherapy.
    Guida G; Boita M; Scirelli T; Bommarito L; Heffler E; Badiu I; Bellone G; Mietta S; Mistrello G; Rolla G
    Allergy Asthma Proc; 2012; 33(5):411-5. PubMed ID: 22762741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Birch pollen allergy in Europe.
    Biedermann T; Winther L; Till SJ; Panzner P; Knulst A; Valovirta E
    Allergy; 2019 Jul; 74(7):1237-1248. PubMed ID: 30829410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
    Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
    Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant Mal d 1 facilitates sublingual challenge tests of birch pollen-allergic patients with apple allergy.
    Kinaciyan T; Nagl B; Faustmann S; Kopp S; Wolkersdorfer M; Bohle B
    Allergy; 2016 Feb; 71(2):272-4. PubMed ID: 26443126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
    Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
    J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.